Recent news highlights include a contract extension with the largest customer and quarterly earnings reports showing revenue growth and variability in repair revenues.

• Pro-Dex announced a contract extension with its largest customer, extending supply agreements through 2028 and increasing volumes of new surgical handpieces [N4].
• Pro-Dex reported Q1 earnings and revenues that topped estimates, reflecting growth in medical device sales [N5].
• The company lagged Q4 earnings and revenue estimates in a prior period, with repair revenues declining due to fewer legacy handpiece repairs [N7].
• Pro-Dex’s revenue jumped 16% in fiscal Q4, indicating growth momentum in core business segments [N8].

Pro-Dex’s patented technology and proprietary manufacturing methods have been well received in key surgical markets, including orthopedic and CMF. The contract extension with its largest customer through 2028 and increased volumes of new surgical handpieces support stable revenue streams. The acquisition of APM expands manufacturing capacity and diversifies revenue into aerospace and defense sectors. The company’s investment in research and development, including new product launches like the Helios driver, may enhance its product portfolio and customer appeal. Its strong liquidity and solid profitability metrics provide financial flexibility to support growth initiatives.

Pro-Dex’s business is highly concentrated, with one customer accounting for a large majority of sales, posing customer concentration risk. Repair revenues have declined, possibly reflecting shifts to newer products, which may impact recurring revenue streams. The company operates in a highly competitive market with larger competitors and internal manufacturing groups of customers, which could pressure pricing and market share. Regulatory compliance risks and potential changes in healthcare cost pressures may affect operations. Employee turnover and integration risks related to the APM acquisition could impact execution. The backlog has declined year-over-year, indicating variability in order bookings.

Pro-Dex’s moat is supported by its patented adaptive torque-limiting technology and proprietary sealing solutions, which differentiate its surgical drivers and shavers. The company’s long-term supply agreements with major customers, including a contract extension through 2028 with its largest customer, provide revenue visibility. Its in-house manufacturing capabilities, including the recent acquisition of APM with specialized certifications for aerospace and defense, enhance operational control and capacity. Regulatory certifications such as FDA Establishment Registration and ISO standards compliance support product quality and market acceptance. However, the company faces competition from larger medical device firms and internal manufacturing groups of customers, which may limit pricing power and market share expansion.

• Customer Concentration Risk: One customer accounted for 78% of sales in fiscal 2026, creating dependency risk if this relationship changes.
• Competitive Pressure: The company faces competition from larger medical device companies and internal manufacturing groups, which may affect pricing and market share.
• Regulatory Compliance: Operations are subject to FDA and other regulatory requirements; non-compliance or changes in regulations could adversely affect the business.
• Order Variability and Backlog Decline: Backlog decreased from $50.4 million to $32.9 million year-over-year, indicating variability in new order bookings and potential revenue fluctuations.
• Integration and Operational Risks: The recent acquisition of APM requires effective integration and operational management to realize benefits.

• Pro-Dex, Inc. specializes in designing, developing, and manufacturing autoclavable, battery-powered and electric multi-function surgical drivers and shavers primarily for orthopedic, thoracic, and craniomaxillofacial (CMF) markets [S1].
• The company holds patented adaptive torque-limiting technology and proprietary sealing solutions appealing to medical device distributors [S1].
• Pro-Dex also manufactures and sells rotary air motors to various industries, though this is a minor part of the business [S1].
• Since February 2026, Pro-Dex operates Advanced Precision Machining, LLC (APM), a subsidiary manufacturing precision machined parts and assemblies for aerospace and defense industries, including U.S. government prime contracting with ITAR and JCP certifications [S1].
• The company’s principal headquarters are in Irvine, California, with manufacturing and assembly facilities in Irvine, Tustin, and Costa Mesa, California [S1].
• In fiscal 2026, medical device products accounted for 80% of total sales, industrial and scientific 2%, NRE & prototypes 2%, and repairs 16% [S1].
• Top three customers accounted for 92% of sales in fiscal 2026, with one customer representing 78% of sales and the next largest 8% [S1].
• Pro-Dex’s largest customer extended its supply agreement through calendar 2028, including higher volumes of a new surgical handpiece [S1][N4].
• The company’s backlog was $32.9 million at June 30, 2026, down from $50.4 million a year earlier, representing firm purchase orders expected to be delivered mostly in fiscal 2027 [S1].
• Pro-Dex’s medical device sales increased 36% for the three months ended March 31, 2026, compared to the prior year, driven largely by the largest customer [S2].
• Repair revenues decreased due to fewer repairs of legacy orthopedic handpieces, possibly reflecting customer replacement with next-generation products [S2].
• Research and development expenses were $3.3 million in fiscal 2026, focused on product design and technology advancement, including the Helios driver featuring adaptive torque-limiting software [S1][S2].
• The company acquired a 25,000 square foot industrial building in Tustin, California, to expand manufacturing capacity, operational since fiscal 2023 Q4 [S1].
• Pro-Dex holds FDA Establishment Registration and California Device Manufacturing License for its facilities, with ISO 13485:2016 certification for medical device production and AS9100D & ISO 9001:2015 certifications for APM [S1].
• Financial snapshot as of June 30, 2026, shows cash and equivalents of $8.19 million, short-term investments of $1.15 million, current assets of $53.25 million, current liabilities of $12.98 million, a current ratio of 4.1, and a cash ratio of 0.72 [sec_financial_snapshot].
• Fiscal 2026 revenue was $77.5 million with net income of $13.7 million and basic EPS of $4.24 per share [sec_financial_snapshot].
• The company faces competition from larger medical device companies and internal manufacturing groups of customers, with risks from pricing pressure and market acceptance [S1].
• Pro-Dex’s business is subject to FDA and other regulatory requirements, with risks related to compliance and potential changes in healthcare cost pressures [S1].
• Employee turnover was 21% in fiscal 2026, with 206 employees primarily in California facilities; the company offers competitive compensation and benefits [S1].